BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 38485716)

  • 1. Exploring new mechanisms of Imeglimin in diabetes treatment: Amelioration of mitochondrial dysfunction.
    Li Y; Lou N; Liu X; Zhuang X; Chen S
    Biomed Pharmacother; 2024 Jun; 175():116755. PubMed ID: 38772155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acidic Nanoparticles Restore Lysosomal Acidification and Rescue Metabolic Dysfunction in Pancreatic β-Cells under Lipotoxic Conditions.
    Lo CH; O'Connor LM; Loi GWZ; Saipuljumri EN; Indajang J; Lopes KM; Shirihai OS; Grinstaff MW; Zeng J
    ACS Nano; 2024 Jun; ():. PubMed ID: 38830624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.
    Hallakou-Bozec S; Vial G; Kergoat M; Fouqueray P; Bolze S; Borel AL; Fontaine E; Moller DE
    Diabetes Obes Metab; 2021 Mar; 23(3):664-673. PubMed ID: 33269554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imeglimin: the New Kid on the Block.
    Shrestha SC; Gupta S
    Curr Diab Rep; 2024 Jan; 24(1):13-18. PubMed ID: 38051432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imeglimin mitigates the accumulation of dysfunctional mitochondria to restore insulin secretion and suppress apoptosis of pancreatic β-cells from db/db mice.
    Aoyagi K; Nishiwaki C; Nakamichi Y; Yamashita SI; Kanki T; Ohara-Imaizumi M
    Sci Rep; 2024 Mar; 14(1):6178. PubMed ID: 38485716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imeglimin exerts favorable effects on pancreatic β-cells by improving morphology in mitochondria and increasing the number of insulin granules.
    Sanada J; Obata A; Fushimi Y; Kimura T; Shimoda M; Ikeda T; Nogami Y; Obata Y; Yamasaki Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Sci Rep; 2022 Aug; 12(1):13220. PubMed ID: 35918386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.
    Hallakou-Bozec S; Kergoat M; Moller DE; Bolze S
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00193. PubMed ID: 33855202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new beta cell-specific mitophagy reporter mouse shows that metabolic stress leads to accumulation of dysfunctional mitochondria despite increased mitophagy.
    Aoyagi K; Yamashita SI; Akimoto Y; Nishiwaki C; Nakamichi Y; Udagawa H; Abe M; Sakimura K; Kanki T; Ohara-Imaizumi M
    Diabetologia; 2023 Jan; 66(1):147-162. PubMed ID: 36181536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin alleviates glucolipotoxicity-induced pancreatic β cell ferroptosis through regulation of the GPX4/ACSL4 axis.
    Sun Y; Guo LQ; Wang DG; Xing YJ; Bai YP; Zhang T; Wang W; Zhou SM; Yao XM; Cheng JH; Chang WW; Lv K; Li CX; Kong X
    Eur J Pharmacol; 2023 Oct; 956():175967. PubMed ID: 37549729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective Effects of Imeglimin and Metformin Combination Therapy on β-Cells in db/db Male Mice.
    Nishiyama K; Ono M; Tsuno T; Inoue R; Fukunaka A; Okuyama T; Kyohara M; Togashi Y; Fukushima S; Atsumi T; Sato A; Tsurumoto A; Sakai C; Fujitani Y; Terauchi Y; Ito S; Shirakawa J
    Endocrinology; 2023 Jun; 164(8):. PubMed ID: 37314160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using
    Fauzi M; Murakami T; Fujimoto H; Botagarova A; Sakaki K; Kiyobayashi S; Ogura M; Inagaki N
    Front Endocrinol (Lausanne); 2022; 13():1010825. PubMed ID: 36246910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
    Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
    Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.